CytRx Corporation has initiated a Phase Ib safety and dose escalation clinical trial of INNO-206 in patients with advanced solid tumours.
The clinical trial will enrol up to 24 patients with advanced solid tumours who have failed standard therapies.
INNO-206, a tumour-targeting pro-drug of the commonly prescribed chemotherapeutic doxorubicin, is designed to improve efficacy and reduce adverse events through controlled release and preferential targeting of tumours.
In an earlier Phase I trial, objective clinical responses were observed with INNO-206 in patients with sarcoma, breast and lung cancers.
CytRx president and CEO Steven Kriegsman said that determining the maximum dose of INNO-206 in patients with solid tumours is a major step forward in advancing the oncology drug candidate's development.
"We have already completed drug formulation and manufacturing optimisation in anticipation of moving rapidly into Phase II clinical programmes following completion of this clinical trial," Kriegsman added.